Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Chief Development Officer | August 21, 2023 | August 23, 2023 |
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director | September 09, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date August 21, 2023 · Filed August 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,962 |
Reported balance
After 2023-08-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-21 · Sale · Disposed 1,490 · Balance 26,962 F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022. F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 448 shares, and on March 13, 2023 for 1,183 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022.
F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 448 shares, and on March 13, 2023 for 1,183 shares.
Vistagen Therapeutics, Inc.
Report date September 09, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2035-09-09 | Direct | 17,600 |
Reported balance
After 2025-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-09 · Grant · Acquired 17,600 · Balance 17,600 F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2022 Filed Jul 11, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 3,514 | $2.90 | $10,179.36 |
DisclosureSEC source: 0001209191-22-041771 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 3,487 | $15.03 | $52,420.77 |
DisclosureSEC source: 0001209191-22-041771 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 3,487 | $6.37 | $22,221.95 |
DisclosureSEC source: 0001209191-22-041771 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 22:49 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 1,239 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-039055 · doc4.xml · derivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,906 Underlying: Class A Common Stock · 1,239 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 22:49 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 306 | $15.02 | $4,594.99 |
DisclosureSEC source: 0001209191-22-039055 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.03, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 22:49 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,239 | $15.01 | $18,602.97 |
DisclosureSEC source: 0001209191-22-039055 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,994 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.03, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 22:49 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,239 | $6.37 | $7,895.90 |
DisclosureSEC source: 0001209191-22-039055 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 3,341 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-038582 · doc4.xml · derivative · entry 7 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,681 Underlying: Class A Common Stock · 3,341 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vest on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 1,346 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-038582 · doc4.xml · derivative · entry 6 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,145 Underlying: Class A Common Stock · 1,346 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,200 | $15.05 | $18,060.96 |
DisclosureSEC source: 0001209191-22-038582 · doc4.xml · nonDerivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,994 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.21, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 3,341 | $15.03 | $50,210.89 |
DisclosureSEC source: 0001209191-22-038582 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,194 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.26, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 3,341 | $2.90 | $9,678.21 |
DisclosureSEC source: 0001209191-22-038582 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,346 | $15.08 | $20,293.64 |
DisclosureSEC source: 0001209191-22-038582 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,194 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.33, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,346 | $6.37 | $8,577.79 |
DisclosureSEC source: 0001209191-22-038582 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-033485 · doc4.xml · derivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,491 Underlying: Class A Common Stock · 400 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 400 | $15.22 | $6,086.20 |
DisclosureSEC source: 0001209191-22-033485 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,194 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.10 to $15.53, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 400 | $6.37 | $2,549.12 |
DisclosureSEC source: 0001209191-22-033485 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,461 shares acquired under the Issuer's Employee Stock Purchase Plan on March 11, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:10 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001415889-22-002287 · form4-03032022_010302.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 52,964 | $0.00 Strike: $20.94 | $0.00 |
DisclosureSEC source: 0001209191-22-011224 · doc4.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,964 Underlying: Class A Common Stock · 52,964 shares Expires 2032-02-15 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 16, 2022, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| May 13, 2021 Filed May 18, 2021 00:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 108,217 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033333 · doc4.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,217 Underlying: Class A Common Stock · 108,217 shares Expires 2031-05-12 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:10 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001415889-21-002138 · form4-04272021_010425.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-04-23 F1 · derivative.exercise_date: 25% of the stock options vest on the one-year anniversary of the grant date, with the remaining 75% vesting ratably on a monthly basis over the 36 months thereafter. Stock options were granted in connection with the Reporting Person's appointment to the Issuer's Board of Directors and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.